We want to highlight ongoing Nurses’ Health Study research on breast cancer risk and oral contraceptive use. Our understanding of breast cancer risk continues to grow, and we recognize the need for continuous research on this topic.

History of NHS Research on Oral Contraceptive Use & Breast Cancer
The Nurses’ Health Studies have been researching the relationship between oral contraceptive use (OC) and breast cancer risk since 1976, resulting in 200+ publications. The research has continued over the past 5 decades, with the most recent findings published in 2022.

 Recent Findings (Burchardt et al. 2022)

  • Oral contraceptive use was associated with a higher risk for invasive breast cancer compared with never use. Stronger associations were observed for longer durations of OC use.
  • These associations were observed for select formulations containing levonorgestrel and norgestrel. More research is needed for newer progestin types (desogestrel, norgestimate, drospirenone) due to their limited use in this sample.
  • Breast cancer risk becomes comparable to that of non-users after about 5 years of non-use.

Next Steps

“Different oral contraceptive formulations might convey different risks of breast cancer; ongoing monitoring of these associations is necessary as oral contraceptive formulations change” (Hunter et al., 2010).

2022 Citation
Burchardt et al. (2022). Oral contraceptive use by formulation and breast cancer risk by subtype in the Nurses’ Health Study II: a prospective cohort study. American Journal of Obstetrics & Gynecology, 226, 821.e1-821.e26. 10.1016/j.ajog.2021.12.022